English ministers veto Alexion's ultra orphan Soliris
This article was originally published in Scrip
English health ministers have rejected orphan drugs advisor, AGNSS' recommendation endorsing Alexion's Soliris (eculizumab) for atypical hemolytic uremic syndrome (aHUS). The ministers want more advice on the drug's affordability and are sending it for review by NICE, despite concerns that the health technology appraisal institute's current methods are unsuitable for drugs for rare conditions.
You may also be interested in...
Orphan drugs "are falling through the cracks" of the UK’s market access process, Shire's country general manager tells the Pink Sheet and calls for urgent all-party remedial talks.
Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.
Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.